Paul Audhya Sells 5,296 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 5,296 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the completion of the transaction, the insider owned 131,831 shares in the company, valued at approximately $1,773,126.95. This trade represents a 3.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

KalVista Pharmaceuticals Stock Up 6.2%

NASDAQ KALV opened at $14.10 on Friday. The business’s fifty day simple moving average is $12.04 and its 200-day simple moving average is $12.88. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $17.28. The firm has a market cap of $712.70 million, a PE ratio of -3.58 and a beta of -0.04.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.04. The company had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million. Research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Wall Street Analysts Forecast Growth

KALV has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, October 8th. Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. JMP Securities boosted their price objective on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Friday, September 12th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th. Finally, Citizens Jmp reduced their price target on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research note on Tuesday, November 11th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, KalVista Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $26.63.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its stake in shares of KalVista Pharmaceuticals by 5.1% during the 1st quarter. Bank of New York Mellon Corp now owns 103,530 shares of the specialty pharmaceutical company’s stock worth $1,195,000 after acquiring an additional 4,983 shares in the last quarter. CWM LLC lifted its position in KalVista Pharmaceuticals by 12,636.1% in the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock worth $53,000 after buying an additional 4,549 shares in the last quarter. Earned Wealth Advisors LLC acquired a new stake in KalVista Pharmaceuticals during the first quarter valued at $44,000. Vanguard Group Inc. lifted its holdings in shares of KalVista Pharmaceuticals by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company’s stock valued at $26,526,000 after buying an additional 43,355 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in KalVista Pharmaceuticals by 12.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 113,124 shares of the specialty pharmaceutical company’s stock worth $1,305,000 after acquiring an additional 12,776 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).